Immune Checkpoint Bioassays Power Combination Immunotherapy

Here we present the following bioassays: 

  • Co-inhibitory Bioassays (PD-1, CTLA-4, LAG-3, TIGIT, CD226)
  • Co-stimulatory Bioassays (GITR, 4-1BB, OX40, CD40, HVEM)
  • Combination Bioassay (PD-1+TIGIT)
  • T Cell Activation Bioassays for bispecific antibodies and CAR-T
    cell immunotherapies


Therapeutic antibodies designed to block or activate immune checkpoint receptors are a powerful new approach to the treatment of cancer and other diseases. However, due to their biologic complexity the development of therapeutic antibodies requires unique functional and analytical tools. This webinar highlights the a suite of MOA-based functional bioassays for use in antibody screening, characterization, potency testing and stability studies.



Richard Somberg, PhD
Strategic Collaborations Manager
Promega Corporation

Richard is a Strategic Collaborations Manager focusing on building strategic relationships with biotech and pharmaceutical customers through technical introductions on early access technologies, custom assay services, and collaborative support. Prior to Promega, Dr. Somberg worked at Life Technologies where he led product development and service efforts in biochemical and cell-based assays for key target classes in drug discovery. He received his Ph.D. in immunology from Purdue University and completed post-doctoral studies at the University of Pennsylvania.

We love to talk science.

Sign up to receive monthly invitations to our webinars.

Sign Up